Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
BOC-Ile-N(OCH3)CH3 is a chemical compound that serves as a drug impurity, specifically an N-derivative of isoleucine. This reagent is pivotal in pharmaceutical development and quality control, as it allows for the analysis of drug formulations and the understanding of synthesis pathways. Its relevance in research extends to evaluating the stability and purity of drug substances. -
Drug Impurity
Uradil Impurity 1 is identified as an impurity of Uradil, primarily serving as a reference standard in drug development and quality control. Its presence may affect the safety and efficacy profiles of pharmaceutical formulations, making it critical for analytical characterization. Research applications include stability testing and impurity profiling to ensure compliance with regulatory standards in drug formulation. -
Drug Impurity
2-Cyanoethyl acetoacetate is a chemical compound that serves as a drug impurity. It is significant in analytical chemistry for assessing the purity of pharmaceutical formulations and studying degradation pathways of drug candidates. Researchers utilize this reagent to investigate the stability and quality control of various therapeutic agents. -
Drug Impurity
Nintedanib impurity 3 is a chemical impurity related to Nintedanib, a receptor tyrosine kinase inhibitor. This compound is significant for analytical and quality control purposes in pharmaceutical research and development. Its identification and quantification are crucial for ensuring the safety and efficacy of Nintedanib formulations. -
Drug Impurity
7-Deazapurine impurity 1 is a known impurity associated with the synthesis of purine derivatives. This compound may arise during the production of specific pharmaceuticals and is critical for assessing the purity and quality of drug formulations. Its analysis is essential in pharmaceutical research and development to ensure compliance with regulatory standards. -
Drug Impurity
Linagliptin impurity 34 is a chemical impurity associated with Linagliptin, a DPP-4 inhibitor. This substance is critical for the assessment of drug purity and quality control in pharmaceutical research. Its characterization and analytical evaluation are essential for understanding the metabolic profile and potential safety implications of Linagliptin formulations. -
Drug Impurity
Tofacitinib impurity 32 is a chemical impurity associated with the kinase inhibitor Tofacitinib. Its characterization is essential for assessing the purity and quality of pharmaceutical formulations. This reagent is utilized in research focused on the development and validation of analytical methods for drug analysis, as well as for stability studies in pharmaceutical sciences. -
Drug Impurity
Timolol impurity 1 is a known impurity of the beta-adrenergic antagonist Timolol. Its characterization is essential for quality control in pharmaceutical development, ensuring the purity and safety of the final drug product. This reagent is useful for analytical studies and method validation in drug formulation and stability testing. -
Drug Impurity
Suvorexant impurity 1 is a by-product of Suvorexant synthesis, primarily associated with drug formulation and quality control. This impurity may be utilized in analytical studies to examine the effects of impurities on potency and efficacy in drug development. Research applications include stability testing and profiling of Suvorexant formulations, contributing to better understanding of safety and pharmacokinetics in preclinical studies. -
5-ASA Impurity
3-Aminosalicylic acid is a key impurity associated with the synthesis of 5-Aminosalicylic acid, a known agonist of PPARγ and an inhibitor of p21-activated kinase 1 (PAK1) and NF-κB. This compound is primarily used in research related to inflammatory bowel diseases such as Crohn's disease and ulcerative proctitis. Its role in modulating these pathways makes it significant for studies focused on therapeutic interventions and drug development in gastrointestinal conditions. -
Drug Impurity
Nintedanib impurity 7 is a known impurity associated with Nintedanib, targeting multiple receptor kinase pathways. It serves as a critical reference standard for assessing the purity of Nintedanib formulations in pharmacokinetic studies and quality control. This compound is valuable for researchers examining drug safety, efficacy, and metabolic pathways related to Nintedanib and its therapeutic applications. -
Drug Impurity
Afatinib impurity 36 is a chemical impurity associated with the drug Afatinib, an irreversible ErbB receptor tyrosine kinase inhibitor. This impurity is utilized in the analytical assessment of Afatinib’s purity and quality, aiding in the development and validation of pharmaceutical formulations. Its identification is essential for maintaining compliance with regulatory standards in drug manufacturing. -
Drug Impurity
Cannabidiol impurity 1 is a known impurity derived from Cannabidiol. This compound is often identified during the analysis and purification processes of Cannabidiol formulations. Its presence can impact the purity and potency of cannabinoid products, making it relevant for quality control and regulatory compliance in pharmaceutical and nutraceutical research. -
Drug Impurity
6,7-Dihydropyrazino[2,3-d]pyridazine-5,8-dione is identified as a drug impurity that may arise during the synthesis of pharmaceutical compounds. Its presence can impact the purity and safety profile of drug formulations. This compound is important for research applications that focus on the characterization and quantification of impurities in drug development and quality control processes. -
Drug Impurity
Butenafine impurity 2 is a drug impurity related to Butenafine, a compound primarily used as an antifungal agent. This impurity can be crucial for analytical studies and quality control in pharmaceutical development. Its characterization helps ensure the safety and efficacy of Butenafine formulations in research and clinical applications. -
Drug Impurity
Atenolol impurity 5 (p-Hydroxy pheny lacetamide) serves as a drug impurity of Atenolol. This compound is significant for analytical chemistry applications, particularly in the quality control and pharmacokinetic studies of Atenolol formulations. It aids in assessing the purity and safety profiles of Atenolol and can be utilized in method development for impurity identification and quantification. -
Drug Impurity
Metoprolol Impurity 42 is a known impurity associated with the beta-blocker Metoprolol. This compound is primarily used for analytical research applications to assess drug purity and stability. Its presence may provide insights into the metabolic pathways and degradation products related to Metoprolol, aiding in quality control and regulatory compliance studies. -
Drug Impurity
Ribociclib Impurity 2 is a known impurity associated with the cyclin-dependent kinase 4 and 6 inhibitor Ribociclib. This compound is utilized primarily in the characterization and quantification of drug purity in pharmaceutical formulations. Its presence may affect the pharmacological profile and efficacy of Ribociclib, making it an important compound for quality control and regulatory compliance in drug development and research applications. -
Drug Impurity
Vitamin Impurity 4 is a chemical impurity associated with vitamin compounds, primarily impacting drug safety and efficacy evaluation. This reagent is commonly utilized in quality control assessments within pharmaceutical research, helping to ensure compliance with regulatory standards. Its role as an impurity provides crucial insights into the stability and purity of vitamin formulations, making it an essential tool for researchers involved in vitamin-related studies. -
Drug Impurity
Rebamipide impurity 6 is a known impurity associated with Rebamipide, a therapeutic agent primarily targeting mucosal protection in gastrointestinal disorders. This compound is essential for analytical studies and quality control processes in pharmaceutical research. Its identification and characterization aid in understanding the compound's stability and efficacy profiles. -
Drug Impurity
Vonoprazan impurity 6 is a chemical impurity associated with Vonoprazan, a proton pump inhibitor. It serves as an important reference standard for analytical and quality control purposes in the pharmaceutical industry. The characterization of this impurity aids in ensuring the purity and safety of Vonoprazan formulations, contributing to the rigorous standards of drug development and regulatory compliance. -
Drug Impurity
(S)-Ponesimod is a chiral impurity associated with the selective S1P receptor modulator, Ponesimod. Its presence is relevant in the development and quality control of therapeutic formulations targeting autoimmune diseases. Research applications include assessing drug purity and understanding the pharmacokinetics of S1P receptor modulators. -
Drug Impurity
Quetiapine impurity 25 is a drug impurity related to Quetiapine, an atypical antipsychotic. This impurity may be utilized in the evaluation of the quality and efficacy of pharmaceutical formulations containing Quetiapine. Its characterization is essential for ensuring compliance with regulatory standards and for understanding the metabolic pathways and potential side effects associated with Quetiapine use in clinical settings. -
Methamphetamine Impurity
N-Formylmethamphetamine is identified as an impurity in the synthesis of methamphetamine and serves as a by-product of the Nagai reaction. Its characterization is essential for assessing the purity of methamphetamine samples in research settings. This compound aids in studies focused on understanding synthesis pathways and enhancing analytical methods in forensic toxicology. -
SM-102 Impurity
SM-102 N-Oxide is a structural impurity of the lipophilic compound SM-102. As an important byproduct in lipid-based research, it is utilized primarily to investigate the biophysical properties and efficacy of lipid formulations. Its presence can influence the performance characteristics in applications such as gene delivery and RNA therapeutics. -
Drug Impurity
Rebamipide impurity 1 is a chemical impurity associated with Rebamipide, a gastroprotective agent. This impurity is crucial for analytical and quality control purposes in the evaluation of drug purity and formulation. Researchers can utilize this compound to assess the integrity and stability of Rebamipide in various biological studies and formulations. -
Drug Impurity
Apixaban impurity 28 is a chemical impurity associated with the anticoagulant agent Apixaban. This compound serves as a reference standard for analytical characterization and quality control of Apixaban formulations. Its identification and quantification are critical for ensuring the integrity and safety of pharmaceutical products containing Apixaban, making it valuable for research and development in drug formulation and regulatory compliance. -
Drug Impurity
Ribociclib impurity 1 is a known impurity associated with the CDK4/6 inhibitor Ribociclib. This compound serves as a reference standard for quality control and characterization of Ribociclib formulations. It is essential in analytical applications to ensure the purity and efficacy of ribociclib in pharmaceutical development and research. -
Drug Impurity
Leflunomide impurity 2, also known as 4-Aminobenzotrifluoride, is identified as a drug impurity associated with Leflunomide. This compound may serve as a valuable reference standard for analytical methods aimed at evaluating the purity of Leflunomide formulations, contributing to quality control measures in pharmaceutical research. Its role in drug development underscores the importance of understanding and characterizing potential impurities in therapeutic agents. -
Drug Impurity
Apixaban impurity 2 is a characterized impurity of the anticoagulant Apixaban. Its analysis is critical for assessing the purity and quality of Apixaban formulations. This impurity is useful in regulatory and stability studies, as well as in the development of analytical methods for drug characterization and quality control in pharmaceutical research. -
Drug Impurity
Ondansetron impurity 7 (2-Methyl-1H-imidazole) is a known impurity in the synthesis of Ondansetron. This compound serves as a reference standard for analytical chemistry and quality control processes in pharmaceutical research. It is primarily utilized for assessing the purity of Ondansetron formulations and for studying potential effects associated with impurities in drug development. -
Drug Impurity
Rebamipide impurity 3 is a chemical byproduct associated with the synthesis of Rebamipide, a gastroprotective agent. This impurity may serve as a reference standard in quality control and characterization studies of Rebamipide formulations. Its presence in pharmaceutical preparations is of interest for ensuring product purity and compliance with regulatory standards in drug development. -
Goserelin Impurity
Goserelin EP Impurity E is an impurity of Goserelin that serves as a valuable reference standard in analytical chemistry. It is used primarily for the characterization and quality control of Goserelin formulations in pharmaceutical research. This compound aids in assessing the purity and stability of Goserelin, ensuring that drug preparations meet regulatory standards in therapeutic applications. -
Exenatide Impurity
(D-Asp28)-Exenatide is an impurity of Exenatide, which functions as a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. This compound plays a significant role in the regulation of glucose homeostasis and appetite control, making it relevant for research in diabetes and obesity. The characterization of this impurity is essential for understanding the pharmacological properties and ensuring the quality of Exenatide in therapeutic applications. -
Impurity
5′-Deoxy-5-fluoro-N4-(isopentyloxycarbonyl)cytidine is an impurity associated with the synthesis of Capecitabine. This compound may be used in analytical studies to ensure the purity and quality of Capecitabine preparations. Its identification and characterization contribute to the understanding of the synthesis process and its optimization in pharmaceutical development. -
Heroin Impurity
ATM4 4-Acetoxy analog is identified as an impurity associated with the synthesis of heroin. This compound plays a notable role in chemical research related to opioid synthesis and quality control. Its characterization is crucial for understanding the intricacies of heroin production and ensuring regulatory compliance within drug development processes. -
Amphetamines Impurity
1,2-Dibromo-4,5-methylenedioxybenzene is an impurity associated with the synthesis of amphetamines. This compound is relevant for analytical research and quality control in the production of amphetamine derivatives. Its presence may influence the pharmacological properties of synthesized compounds, making it an important target for study in chemical research focused on amphetamine-related substances. -
Impurity of Valsartan
D-Valsartan is an impurity of Valsartan, which functions primarily as an angiotensin II receptor antagonist. It plays a critical role in the characterization of Valsartan and is essential for purity assessments during pharmaceutical development. This compound serves as a reference in research applications aimed at understanding the pharmacological profile and safety of angiotensin II receptor modulators. -
Process-related Impurity
NW-1689 is a process-related impurity of safinamide mesilate (SAFM) and exhibits similar chemical characteristics. It functions primarily as a reversible inhibitor of monoamine oxidase-B (MAO-B) and shares pharmacological properties with SAFM, contributing to reduced dopamine degradation and glutamate release. This compound is relevant for research focused on Parkinson's disease, supporting investigations into neuroprotective mechanisms and potential therapeutic effects. -
Amide Impurity
Citalopram impurity 1 is an amide impurity that arises during the synthetic production of Citalopram. This compound can be utilized in quality control and analytical studies to assess the purity of Citalopram formulations. It serves as an important reference material for researchers engaged in pharmacological studies and drug development processes involving Citalopram. -
Drug Impurity
Atenolol impurity 8 is a structural impurity associated with Atenolol, a selective beta-1 adrenergic receptor blocker. This compound is crucial for analyzing the purity of Atenolol formulations and evaluating potential impacts on drug efficacy and safety. It serves as an important reference standard in the pharmaceutical industry for quality control and compliance in drug development and analysis. -
Drug Impurity
Ranolazine impurity 3 is a chemical impurity associated with Ranolazine, primarily used as a reference standard in analytical and quality control applications. This compound is essential for ensuring the purity and consistency of Ranolazine formulations. Its characterization contributes to the understanding of metabolic pathways and the identification of potential degradation products. Research involving this impurity aids in enhancing the quality of pharmaceutical formulations and supports regulatory compliance in drug development processes. -
Drug Impurity
Olmesartan impurity 1 serves as a structural impurity related to the antihypertensive agent Olmesartan. This compound is essential for the analytical characterization of Olmesartan, particularly in the context of quality control and regulatory compliance in pharmaceutical development. Its presence and quantification can provide insights into the synthesis purity and stability profiles of Olmesartan formulations. -
Drug Impurity
Rivaroxaban impurity 67 is a defined impurity of the anticoagulant Rivaroxaban. This compound serves as a critical reference standard for analytical and quality control processes in the pharmaceutical industry. It aids in routine testing, stability analysis, and ensuring the purity of Rivaroxaban formulations in drug development and regulatory compliance. -
Drug Impurity
Cabozantinib impurity 7 is a synthetic impurity derivative of the tyrosine kinase inhibitor Cabozantinib. It serves as a crucial reference standard for quality control and analytical studies related to Cabozantinib production. This compound aids in the characterization and assessment of drug purity, essential for pharmacokinetics and toxicological research applications. -
Drug Impurity
Estradiol impurity 1 is a known impurity associated with the synthesis of Estradiol. This compound can serve as a critical reference for assessing the purity of Estradiol formulations in research and quality control applications. It is important for researchers studying the metabolism and pharmacokinetics of estrogenic compounds, as well as in the evaluation of drug safety and efficacy. -
Drug Impurity
Lifitegrast impurity 4 hydrochloride is a chemical impurity associated with Lifitegrast, primarily known for its role as a lymphocyte function-associated antigen-1 (LFA-1) antagonist. This impurity serves as a reference standard for analytical characterization and quality control in pharmacological studies of Lifitegrast. Research applications include assessing the purity of the active pharmaceutical ingredient and evaluating potential effects on drug efficacy and safety profiles. -
Drug Impurity
Sitagliptin impurity 25 is a known impurity associated with the DPP-4 inhibitor Sitagliptin, primarily targeting the Dipeptidyl Peptidase-4 enzyme. This compound is essential for quality control in the synthesis and analysis of Sitagliptin and is relevant for pharmacokinetic and toxicological studies. Its characterization supports research into drug formulation and regulatory compliance. -
Drug Impurity
Tamsulosin Impurity 6 serves as a drug impurity associated with the pharmaceutical compound tamsulosin. Its presence is critical for quality control and regulatory compliance during the manufacturing process. This compound is utilized in research applications to investigate the safety and efficacy of tamsulosin formulations, contributing to the understanding of potential impacts on drug performance and stability. -
Drug Impurity
Donepezil impurity 10 is a known impurity associated with the compound Donepezil, a reversible inhibitor of the enzyme acetylcholinesterase. This reagent is significant for analytical studies aimed at monitoring the purity of Donepezil in pharmaceutical formulations. It serves as a reference standard in quality control processes and method development, ensuring compliance with regulatory guidelines in drug manufacturing and research applications.
